HUE057245T2 - Gyógyászati készítmény nem-alkoholos zsírmájbetegség megelõzésére vagy kezelésére - Google Patents

Gyógyászati készítmény nem-alkoholos zsírmájbetegség megelõzésére vagy kezelésére

Info

Publication number
HUE057245T2
HUE057245T2 HUE13757286A HUE13757286A HUE057245T2 HU E057245 T2 HUE057245 T2 HU E057245T2 HU E13757286 A HUE13757286 A HU E13757286A HU E13757286 A HUE13757286 A HU E13757286A HU E057245 T2 HUE057245 T2 HU E057245T2
Authority
HU
Hungary
Prior art keywords
prevention
treatment
pharmaceutical composition
liver disease
fatty liver
Prior art date
Application number
HUE13757286A
Other languages
English (en)
Inventor
Se Young Lim
Sung Hee Park
Ryoung Ae Shin
In Young Choi
Se Chang Kwon
Original Assignee
Hanmi Science Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Hanmi Science Co Ltd filed Critical Hanmi Science Co Ltd
Publication of HUE057245T2 publication Critical patent/HUE057245T2/hu

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/26—Glucagons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/28—Insulins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
    • A61K47/59—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes
    • A61K47/60—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes the organic macromolecular compound being a polyoxyalkylene oligomer, polymer or dendrimer, e.g. PEG, PPG, PEO or polyglycerol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6835—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
    • A61K47/6883—Polymer-drug antibody conjugates, e.g. mitomycin-dextran-Ab; DNA-polylysine-antibody complex or conjugate used for therapy
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/48—Drugs for disorders of the endocrine system of the pancreatic hormones
    • A61P5/50—Drugs for disorders of the endocrine system of the pancreatic hormones for increasing or potentiating the activity of insulin
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/575—Hormones
    • C07K14/605—Glucagons
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/40—Immunoglobulins specific features characterized by post-translational modification
    • C07K2317/41—Glycosylation, sialylation, or fucosylation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/75—Agonist effect on antigen
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/94—Stability, e.g. half-life, pH, temperature or enzyme-resistance

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Endocrinology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Diabetes (AREA)
  • Zoology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Biotechnology (AREA)
  • Toxicology (AREA)
  • Emergency Medicine (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Medicinal Preparation (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
HUE13757286A 2012-03-09 2013-03-08 Gyógyászati készítmény nem-alkoholos zsírmájbetegség megelõzésére vagy kezelésére HUE057245T2 (hu)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
KR1020120024632A KR101665009B1 (ko) 2012-03-09 2012-03-09 비알콜성 지방간 질환의 예방 또는 치료용 약학적 조성물

Publications (1)

Publication Number Publication Date
HUE057245T2 true HUE057245T2 (hu) 2022-04-28

Family

ID=49117073

Family Applications (1)

Application Number Title Priority Date Filing Date
HUE13757286A HUE057245T2 (hu) 2012-03-09 2013-03-08 Gyógyászati készítmény nem-alkoholos zsírmájbetegség megelõzésére vagy kezelésére

Country Status (25)

Country Link
US (1) US20150056223A1 (hu)
EP (1) EP2838549B1 (hu)
JP (4) JP2015510880A (hu)
KR (1) KR101665009B1 (hu)
CN (2) CN110075277A (hu)
AR (1) AR090287A1 (hu)
AU (1) AU2013228152C1 (hu)
CA (1) CA2864250C (hu)
DK (1) DK2838549T3 (hu)
ES (1) ES2900823T3 (hu)
HK (1) HK1199220A1 (hu)
HU (1) HUE057245T2 (hu)
IL (1) IL234133B (hu)
IN (1) IN2014DN06694A (hu)
MX (2) MX2014010542A (hu)
MY (1) MY167214A (hu)
NZ (1) NZ628828A (hu)
PH (1) PH12014501785B1 (hu)
PL (1) PL2838549T3 (hu)
PT (1) PT2838549T (hu)
RU (1) RU2635966C2 (hu)
SG (1) SG11201404733UA (hu)
TW (2) TWI658835B (hu)
WO (1) WO2013133667A1 (hu)
ZA (1) ZA201405918B (hu)

Families Citing this family (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TWI601744B (zh) 2011-06-17 2017-10-11 韓美科學股份有限公司 包含調酸素與免疫球蛋白片段之複合物及其用途
KR101968344B1 (ko) 2012-07-25 2019-04-12 한미약품 주식회사 옥신토모듈린 유도체를 포함하는 고지혈증 치료용 조성물
TWI602583B (zh) 2012-11-06 2017-10-21 韓美藥品股份有限公司 包含調酸素及免疫球蛋白片段之蛋白質接合物的液態製劑
BR112016016578A2 (pt) 2014-01-20 2017-10-03 Hanmi Pharm Ind Co Ltd Insulina de ação prolongada e uso daanálogo de insulina, polinucleotídeo, vetor de expressão, transformante, insulina de ação prolongada bem como seu método de preparação e formulação da mesma, conjugado, e uso do mesmo mesma
AR100639A1 (es) 2014-05-29 2016-10-19 Hanmi Pharm Ind Co Ltd Composición para tratar diabetes que comprende conjugados de análogos de insulina de acción prolongada y conjugados de péptidos insulinotrópicos de acción prolongada
AR100695A1 (es) 2014-05-30 2016-10-26 Hanmi Pharm Ind Co Ltd Composición para el tratamiento de diabetes mellitus que comprende insulina y un agonista dual glp-1 / glucagón
TWI802396B (zh) 2014-09-16 2023-05-11 南韓商韓美藥品股份有限公司 長效glp-1/高血糖素受體雙促效劑治療非酒精性脂肝疾病之用途
KR102418477B1 (ko) 2014-12-30 2022-07-08 한미약품 주식회사 글루카곤 유도체
UY36870A (es) 2015-08-28 2017-03-31 Hanmi Pharm Ind Co Ltd Análogos de insulina novedosos
WO2017052329A1 (en) 2015-09-24 2017-03-30 Hanmi Pharm. Co., Ltd. Protein complex by use of a specific site of an immunoglobulin fragment for linkage
TWI774694B (zh) 2016-09-23 2022-08-21 南韓商韓美藥品股份有限公司 具有降低對胰島素受體之親和力之胰島素類似物及其用途
KR101906333B1 (ko) 2016-12-07 2018-10-11 고려대학교 산학협력단 지방간의 진단 또는 치료를 위한 류신 지퍼 단백질의 용도
KR101964743B1 (ko) 2017-01-19 2019-08-14 울산대학교 산학협력단 Gnpat을 유효성분으로 포함하는 비알콜성 지방간염 진단용 또는 치료 예후 예측용 바이오마커 조성물
BR112019019823A2 (pt) 2017-03-23 2020-04-22 Hanmi Pharm Ind Co Ltd conjugado, composição farmacêutica para prevenir ou tratar diabetes e método para tratamento de diabetes
CN109248323B (zh) * 2017-07-14 2023-09-08 杭州先为达生物科技有限公司 酰化的glp-1衍生物
EP3437651A1 (en) * 2017-08-03 2019-02-06 Université de Strasbourg Peptides for treatment and prevention of nonalcoholic fatty liver disease
KR102174436B1 (ko) * 2017-08-17 2020-11-04 주식회사 엘지화학 불용성 안료 화합물의 정성분석방법
KR20200135618A (ko) 2019-05-23 2020-12-03 ㈜ 디앤디파마텍 폴리펩티드를 포함하는 비알코올성 지방간 질환의 예방 또는 치료용 약학 조성물
JP2021530533A (ja) 2018-07-19 2021-11-11 ディーアンドディー ファーマテック インコーポレイテッド ポリペプチドを含む医薬組成物
KR102177304B1 (ko) * 2018-07-23 2020-11-10 제이투에이치바이오텍 (주) 비알콜성 지방간염의 예방 또는 치료용 약학 조성물
CN110151980B (zh) * 2019-06-30 2022-12-09 中国药科大学 Glp-1受体激动剂融合蛋白在制备预防或治疗高血脂药物中的应用
KR102315866B1 (ko) * 2020-03-24 2021-10-21 한국원자력의학원 섬유화 질환 복합 치료제 개발

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5545618A (en) 1990-01-24 1996-08-13 Buckley; Douglas I. GLP-1 analogs useful for diabetes treatment
US5424686A (en) 1994-04-20 1995-06-13 Philips Electronics North America Corporation Negative-resistance-compensated microwave buffer
US6096871A (en) 1995-04-14 2000-08-01 Genentech, Inc. Polypeptides altered to contain an epitope from the Fc region of an IgG molecule for increased half-life
JP4046354B2 (ja) 1996-03-18 2008-02-13 ボード オブ リージェンツ，ザ ユニバーシティ オブ テキサス システム 増大した半減期を有する免疫グロブリン様ドメイン
KR101135244B1 (ko) * 2007-11-29 2012-04-24 한미사이언스 주식회사 인슐린 분비 펩타이드 결합체를 포함하는 비만 관련질환 치료용 조성물
US8263084B2 (en) * 2003-11-13 2012-09-11 Hanmi Science Co., Ltd Pharmaceutical composition for treating obesity-related disease comprising insulinotropic peptide conjugate
AU2004293133A1 (en) * 2003-11-25 2005-06-09 High Point Pharmaceuticals, Llc Novel salicylic anilides
WO2007022518A2 (en) * 2005-08-19 2007-02-22 Amylin Pharmaceuticals, Inc. New uses of glucoregulatory proteins
JP2008169195A (ja) * 2007-01-05 2008-07-24 Hanmi Pharmaceutical Co Ltd キャリア物質を用いたインスリン分泌ペプチド薬物結合体
WO2008108439A1 (ja) * 2007-03-06 2008-09-12 Bridgestone Corporation ゴムクローラ
US8249718B2 (en) * 2008-07-11 2012-08-21 Medtronic, Inc. Programming posture state-responsive therapy with nominal therapy parameters
NZ590358A (en) * 2008-07-23 2012-04-27 Hanmi Holdings Co Ltd A polypeptide complex comprising non-peptidyl polymer having three functional ends
EP2248449A1 (en) * 2009-05-08 2010-11-10 Koninklijke Philips Electronics N.V. Kitchen appliance
WO2011109787A1 (en) * 2010-03-05 2011-09-09 Conjuchem, Llc Methods of administering insulinotropic peptides
KR101382593B1 (ko) * 2010-07-21 2014-04-10 한미사이언스 주식회사 신규한 지속형 글루카곤 결합체 및 이를 포함하는 비만 예방 및 치료용 약학적 조성물

Also Published As

Publication number Publication date
KR101665009B1 (ko) 2016-10-11
JP2018009022A (ja) 2018-01-18
AR090287A1 (es) 2014-11-05
JP2019214627A (ja) 2019-12-19
AU2013228152A1 (en) 2014-09-04
IN2014DN06694A (hu) 2015-05-22
ZA201405918B (en) 2015-08-26
RU2635966C2 (ru) 2017-11-17
JP2022025114A (ja) 2022-02-09
RU2014133615A (ru) 2016-04-27
AU2013228152C1 (en) 2017-11-23
MX2014010542A (es) 2014-12-05
PH12014501785A1 (en) 2014-11-17
DK2838549T3 (da) 2022-01-03
MY167214A (en) 2018-08-14
SG11201404733UA (en) 2014-09-26
EP2838549A1 (en) 2015-02-25
EP2838549B1 (en) 2021-09-22
CA2864250C (en) 2022-08-16
CN110075277A (zh) 2019-08-02
HK1199220A1 (en) 2015-06-26
AU2013228152B2 (en) 2017-08-10
TW201919688A (zh) 2019-06-01
US20150056223A1 (en) 2015-02-26
NZ628828A (en) 2016-09-30
PT2838549T (pt) 2021-12-31
ES2900823T3 (es) 2022-03-18
JP2015510880A (ja) 2015-04-13
WO2013133667A1 (en) 2013-09-12
IL234133B (en) 2020-09-30
PH12014501785B1 (en) 2014-11-17
CN104159597A (zh) 2014-11-19
MX2020001697A (es) 2020-03-20
TWI658835B (zh) 2019-05-11
KR20130103190A (ko) 2013-09-23
CA2864250A1 (en) 2013-09-12
EP2838549A4 (en) 2015-12-23
TW201340981A (zh) 2013-10-16
PL2838549T3 (pl) 2022-02-14

Similar Documents

Publication Publication Date Title
HK1199220A1 (en) Pharmaceutical composition for the prevention or treatment of non- alcoholic fatty liver disease
PL2832365T3 (pl) Kompozycja farmaceutyczna do leczenia i/lub zapobiegania nowotworowi wątroby
HK1218078A1 (zh) 非酒精性脂肪性肝病治療劑
IL231512B (en) Preparations of galacto-rhamnogalacturonate for the treatment of non-alcoholic steatohepatitis and alcoholic fatty liver disease
IL236221A (en) History of theophyridone and pharmacological preparations containing them for the treatment of diseases
EP2818482A4 (en) PHARMACEUTICAL COMPOSITION FOR THE TREATMENT AND / OR PREVENTION OF CANCER
HUE046788T2 (hu) Gyógyászati készítmény rák kezelésére és/vagy megelõzésére
EP2824114A4 (en) PHARMACEUTICAL COMPOSITION FOR THE TREATMENT AND / OR PREVENTION OF CANCER
LT2925757T (lt) Junginiai ir kompozicijos, skirti parazitinių ligų gydymui
EP2549997A4 (en) PHARMACEUTICAL COMPOSITION FOR THE PREVENTION OR TREATMENT OF NON ALCOHOLIC HEALING STEATOSIS AND METHOD FOR THE PREVENTION OR TREATMENT OF NON ALCOHOLIC HEALING STEATOSIS USING THE SAME
SI3378862T1 (sl) Dihidropirimidinoizokuinolini in farmacevtski sestavki le-teh za zdravljenje multiple skleroze
EP2488180A4 (en) PHARMACEUTICAL COMPOSITIONS FOR THE TREATMENT / PROPHYLAXIS OF NON ALCOHOLIC HEPATIC STEATOSIS
HK1215794A1 (zh) 用於治療疾病的同種異體自噬體富集組合物
IL238071B (en) Pharmaceutical composition of 1-adamantylethyloxy-3-morpholino-2-propanol or pharmaceutically acceptable salts thereof for the treatment of cardiovascular disease
HUE037176T2 (hu) Olaj-alapú gyógyszerészeti készítmény gasztrointesztinális betegségek kezelésére
PL2812351T3 (pl) Kompozycja farmaceutyczna do leczenia stwardnienia rozsianego
GB201317059D0 (en) Gene therapy compositions for use in the prevention and/or treatment of non-alcoholic fatty liver disease
IL221238A0 (en) Pharmaceutical compositions and methods for the treatment and prevention of cancer
HK1157189A1 (en) Pharmaceutical composition for the treatment of tumor diseases